Latest Platform Technology News

Imricor Medical Systems has officially launched its US commercial operations, securing Rady Children’s Hospital–San Diego as the first customer for its NorthStar iMR mapping system, following key FDA clearances including pediatric approvals.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.

ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.

Netwealth has broadened its partnership with Morgan Stanley Wealth Management Australia by providing a new domestic platform for ASX equities and investments, underpinning robust FY26 fund inflows and an optimistic FY27 outlook.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

Temas Resources' re-assay program at the Hervieux West deposit validates extensive high-grade titanium-vanadium mineralisation and reveals significant gallium, scandium, and chromium credits, accelerating resource development at the La Blache Project.

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

hipages Group has acquired a majority stake in VIZ Insurance, marking its strategic entry into the insurance sector for tradies and broadening its platform offerings.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Netwealth delivered a resilient March quarter with $4 billion in net inflows, pushing total funds under administration to $125.8 billion despite a 3.7% market dip. Growth in Managed Accounts and new intermediary relationships underpin ongoing momentum.